{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:13:44Z","timestamp":1761920024427,"version":"build-2065373602"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are relentlessly progressive neurodegenerative diseases leading to severe disability and ultimately death within less than 10 y. Despite increasing efforts in basic and clinical research, effective therapies for these atypical parkinsonian disorders are lacking. Although earlier small clinical studies in MSA and PSP mainly focused on symptomatic treatment, advances in the understanding of the molecular underpinnings of these diseases and in the search for biomarkers have paved the way for the first large and well\u2010designed clinical trials aiming at disease modification. Targets of intervention in these trials have included \u03b1\u2010synuclein inclusion pathology in the case of MSA and tau\u2010related mechanisms in PSP. Since 2013, four large randomized, placebo\u2010controlled, double\u2010blind disease\u2010modification trials have been completed and published, using rasagiline (MSA), rifampicin (MSA), tideglusib (PSP), or davunetide (PSP). All of these failed to demonstrate signal efficacy with regard to the primary outcome measures. In addition, two randomized, placebo\u2010controlled, double\u2010blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. This review summarizes the design and the outcomes of these and other smaller trials published since 2013 and attempts to highlight priority areas of future therapeutic research in MSA and PSP. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.26334","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T09:28:25Z","timestamp":1438248505000},"page":"1528-1538","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic advances in multiple system atrophy and progressive supranuclear palsy"],"prefix":"10.1002","volume":"30","author":[{"given":"Werner","family":"Poewe","sequence":"first","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Mahlknecht","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"},{"name":"Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience and Movement Disorders UCL Institute of Neurology London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Krismer","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck Innsbruck Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23829"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2014.02.007"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq115"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn291"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25181"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70327-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20255"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23612"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2011.01234.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200504035"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300227200"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6655-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e32830b3661"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70301-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04777.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.005"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.07.020"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22402"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70073-4"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.11.022"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70288-1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907123010202"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90230-M"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540370036033"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.1.120"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2006.00189.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000083721.49847.D7"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04035"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1381739"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22023"},{"issue":"1","key":"e_1_2_7_37_1","first-page":"265","article-title":"Effects of coenzyme Q10 in PSP, a multicenter, randomized, placebo\u2010controlled, double\u2010blind study [abstr]","volume":"29","author":"Apetauerova D","year":"2014","journal-title":"Mov Disord"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.131"},{"key":"e_1_2_7_39_1","unstructured":"N\u00fcblingG PaulS HenslerM AbrightC CrispinA LorenzlS.The PROSPERA study: a randomized placebo\u2010controlled single center trial to evaluate the safety and efficacy of rasagiline in progressive supranuclear palsy [abstr]. Jahrestagung der Deutschen Gesellschaft f\u00fcr Neurologie. Dresden2013."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70088-2"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.02.011"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70042-0"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/352805"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25824"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25815"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.06.032"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70252-2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2014.00327"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.136069"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70022-4"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.03.046"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910723107"},{"key":"e_1_2_7_53_1","first-page":"12","article-title":"Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study","author":"Giordano R","year":"2014","journal-title":"J Transl Med"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26334","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:08:01Z","timestamp":1760958481000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1002\/mds.26334"],"URL":"https:\/\/doi.org\/10.1002\/mds.26334","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}